Presentation on theme: "516 (32723) Phase III trial comparing AC (x4) taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02."— Presentation transcript:
516 (32723) Phase III trial comparing AC (x4) taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02 trial (Japan) T. Watanabe, M. Kuranami, K. Inoue, N. Masuda, K. Aogi, H. Iwata, H. Mukai, S. Tanaka, T. Yamaguchi, Y. Ohashi
Background Doxorubicin and cyclophosphamide (AC) x 4 paclitaxel x 4 is a standard regimen for postoperative chemotherapy. Rare but serious side effects (e.g., cardiac failure, secondary leukemia) are major concerns with AC. AC cannot be used in some patients. Relative efficacy of docetaxel to that of paclitaxel needs to be clarified.
Trial Design ACP ACD PTX DTX Pts with BCS received RT. Pts with ER(+) BC received TAM or an AI for 5 yrs. weeks ADM 60 mg/m 2 CPA 600 mg/m 2 Paclitaxel 175 mg/m 2 Docetaxel 75 mg/m 2 RANDOMIZE
Primary objectives To compare disease-free survival (DFS) with AC (x4) taxane (x4) vs. taxane (x8) To compare DFS with paclitaxel (x8) vs. docetaxel (x8) in node-positive breast cancer
Exploratory analyses To find subsets of patients who benefit from additional treatment with AC Subsets: HER2 positive vs. HER2 negative or unknown ER positive vs. ER negative or unknown
Inclusion Criteria Stage I to IIIA invasive breast cancer Histologically involved axillary lymph nodes Age years PS (ECOG) 0, 1 No prior chemotherapy or endocrine therapy Adequate organ functions Written informed consent
Statistical Considerations Hypothesis 1: A taxane (x8) is not inferior to AC (x4) a taxane (x4) Hypothesis 2: One of the taxanes is superior or equivalent to the other. Planned N = 1200 (based on planned events (≥320) in hypothesis 1) =0.05; 1-sided (non-inferiority); power (1- ) = 0.80
Patient accrual Between December 2001 and April 2006, 1060 patients were randomized at 84 institutions in Japan. Date of first analysis: June 15, 2008
Patient characteristics (1) ACP (n=260) ACD (n=262) PTX (n=263) DTX (n=259) Age （ mean±sd ） 52.8± ± ± ±8.6 Stage I II A II B III A Pathological tumor size <3 cm ≥3 cm Number of positive lymph nodes
Patient characteristics (2) ACPACDPTXDTX Estrogen Receptor positive negative not tested3253 Progesterone Receptor positive negative unknown 4254 Type of surgery Breast conserving surgery Mastectomy Others HER2 (HercepTest ® ) unknown
Grade ¾ adverse events (%) (1) ACPACDPTXDTX Neutropenia Leukopenia 3502 Thrombocytopenia 0000 Anemia 0000 Febrile neutropenia Elevated AST or ALT 2120 Elevated bilirubin 0000 Edema Pleural effusion 0000 Ascites 0000 Body weight gain 0000 Hair loss 0000 Phlebitis (injection site) 0000 Nail changes 0000
Disease-free Survival Time from randomization （ years ） ： ACP ： ACD ： PTX ： DTX ～～～～～～ Percent probability
Disease-free Survival Summary of events (disease-free survival) ACPACDPTXDTX No. of pts Hypothesis 1: A taxane alone is not inferior to AC + a taxane Hazard ratio (AC + a taxane as standard) % CI % CI p value0.67 Hypothesis 2: Whether PTX or DTX is more effective Hazard ratio (PTX as standard) % CI % CI p value0.08 ・ Two confidence intervals are calculated for each endpoint, taking into account multiplicity due to interim analysis. ・ Final analysis will be planned number of events (>=320) are observed.
Disease-free Survival Time from randomization （ years ） ： AC –> Taxane ： Taxane ～～～～～～ Percent probability Hazard ratio (99%CI) ： 1.26(0.92 – 1.72) Time from randomization （ years ） ： ACD+DTX ： ACP+PTX ～～～～～～ Hazard ratio (99.5%CI) ： 0.81(0.57 – 1.14)
AC Taxane vs. Taxane Subset according to HER2 Time from randomization （ years ） ： AC Taxane ： Taxane ～～～～～～ Percent probability Hazard ratio (95% CI): 1.63(1.05 – 2.54) HER2 positive Time from randomization （ years ） ： AC Taxane ： Taxane ～～～～～～ Hazard ratio (95% CI): 1.13(0.85 – 1.50) HER2 negative/unknown ・ Interactions between the response to AC and HER-2 positive/HER-2 negative/unknown status, P=0.17
AC Taxane vs. Taxane Subset according to ER ER positive ER negative Percent probability ～～～～ Hazard ratio (95%CI) ： 1.32(0.90 – 1.95) ： AC Taxane ： Taxane Time from randomization （ years ） ： AC Taxane ： Taxane ～～～～～～ Hazard ratio (95%CI) ： 1.22(0.90 – 1.66) Time from randomization （ years ）
Summary (1) Taxane (x8) is not demonstrated to be non-inferior to AC (x4) a taxane (x4) in the study group as a whole in terms of DFS. Docetaxel (75 mg/m 2 ) is superior to paclitaxel (175 mg/m 2 ) when given every 3 weeks in terms of DFS. In the subset of HER2-positive patients, AC (x4) a taxane (x4) produced superior DFS than did a taxane (x8). This result was not obtained in patients with HER2-negative or unknown tumors. For ER, there was no interaction with the addition of AC.
Summary (2) Regarding the incidences of adverse events: –Nausea and vomiting were higher with AC (x4) a taxane (x4) than with taxane (x8). –Edema and febrile neutropenia were higher with docetaxel (75 mg/m 2 ) than with paclitaxel (175 mg/m 2 ). –Sensory neuropathy was higher with paclitaxel (175 mg/m 2 ) than with docetaxel (75 mg/m 2 ).
Conclusions AC can be omitted in certain subsets of patients with postoperative breast cancer. When given every 3 weeks, docetaxel (75 mg/m 2 ) improves DFS in women with node-positive breast cancer as compared with paclitaxel (175 mg/m 2 ). The expression of HER2 may be associated with a benefit from the addition of AC.